Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2016 - 2026)

Lineage Cell Therapeutics has reported Long-Term Deferred Tax for 8 years, with the latest figure at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.8 million (changed N/A YoY), and the FY2025 full-year result was $5.8 million, up 2024.54% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $5.8 million, roughly flat from $5.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $5.8 million in Q4 2025, with the low at $273000.0 in Q4 2024.
• Historically, Long-Term Deferred Tax has averaged $4.0 million across 3 years, with a median of $5.8 million in 2025.
• The largest YoY upside for Long-Term Deferred Tax was 2024.54% in 2025 against a maximum downside of 2024.54% in 2025.
• Lineage Cell Therapeutics' Long-Term Deferred Tax stood at $273000.0 in 2024, then jumped by 2024.54% to $5.8 million in 2025, then changed by 0.0% to $5.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $5.8 million (Q1 2026), $5.8 million (Q4 2025), and $273000.0 (Q4 2024), per Business Quant data.